A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir DOI Creative Commons
Luke B. Snell, Aimée McGreal-Bellone, Clemency Nye

и другие.

Open Forum Infectious Diseases, Год журнала: 2023, Номер 11(1)

Опубликована: Дек. 7, 2023

The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where SARS-CoV-2 was successfully treated prolonged courses (median, 10 days [range, 10-18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most (9/11) had hematological malignancy and (10/11) received CD20-depleting therapy. median duration 103 (interquartile range, 85-138 days). majority were hospitalized, 7 (7/11) severe/critical disease. All survived 9 demonstrated viral clearance, almost half (4/9) whom as monotherapy. This series suggests that has a role treating infection.

Язык: Английский

An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity DOI Creative Commons

Emma Chang-Rabley,

Menno C. van Zelm, Emily Ricotta

и другие.

Vaccines, Год журнала: 2024, Номер 12(6), С. 675 - 675

Опубликована: Июнь 18, 2024

The SARS-CoV-2 pandemic has heightened concerns about immunological protection, especially for individuals with inborn errors of immunity (IEI). While COVID-19 vaccines elicit strong immune responses in healthy individuals, their effectiveness IEI patients remains unclear, particularly against new viral variants and vaccine formulations. This uncertainty led to anxiety, prolonged self-isolation, repeated vaccinations uncertain benefits among patients. Despite some level response from vaccination, the definition protective is still unknown. Given susceptibility severe COVID-19, strategies such as immunoglobulin replacement therapy (IgRT) monoclonal antibodies have been employed provide passive immunity, protection both current emerging variants. review examines efficacy antibody-based therapies patients, capacity recognize variants, necessary advances required ongoing people IEIs.

Язык: Английский

Процитировано

1
Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023) DOI Creative Commons
Samya Van Coillie,

J Prévot,

Silvia Sánchez‐Ramón

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Июнь 27, 2024

The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its second Global Multi-Stakeholders’ Summit, an annual stimulating and forward-thinking meeting uniting experts to anticipate pivotal upcoming challenges opportunities in the field of primary immunodeficiency (PID). 2023 summit focused on three key identified discussion points: (i) How can immunoglobulin (Ig) therapy meet future personalized patient needs? (ii) Pandemic preparedness: what’s next public health potential PID community? (iii) Diagnosing PIDs 2030: what needs happen diagnose better more? Clinician-Scientists, representatives other stakeholders explored avenues improve Ig through mechanistic insights tailored preparations/products according patient-specific local exposure infectious agents, amongst others. Urgency pandemic preparedness was discussed, as threat shortage antibiotics increasing antimicrobial resistance, emphasizing need representation patients vulnerable populations throughout crisis care management. Discussion also covered complexities diagnosis, addressing issues such global diagnostic disparities, integration patient-reported outcome measures, artificial intelligence increase diagnosis rates enhance precision. These proceedings outline outcomes recommendations arising from IPOPI offering valuable inform strategies management care. Integral this initiative is role fostering collaborative efforts among prepare multiple facing community.

Язык: Английский

Процитировано

1
Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy DOI Creative Commons

Mark Ballow,

Raúl Ortiz-de-Lejarazu,

Isabella Quinti

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Окт. 22, 2024

Seasonal and pandemic influenza infection present a potential threat to patients with antibody deficiency. The acceptance effect of the current recommendation for annual vaccination against deficiency is not well investigated due antigenic drift or shift protective capacity regular IgG replacement therapy (IgRT) considered low. This narrative review considers in immunodeficient discusses available information on immunoglobulin products seasonal infectivity severity receiving IgRT. humoral immune response reduced However, there no evidence that proportion primary who develop illness, such increased when compared general population. IgRT receive has been shown contain neutralizing antibodies as consequence past flu infections both hemagglutinin neuraminidase surface proteins other viral internal different A virus strains. Studies have demonstrated only significant levels specific but also cross-reactive Thus, despite yearly changes antigenicity occur, could potentially contribute protection influenza. Currently, limited clinical data are confirming preventative respect infection. In conclusion, some antibody-related immunodeficiency. additional needed confirm extent relevance this identify main responsible targets protection.

Язык: Английский

Процитировано

1
Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Replacement Therapy for Immunocompromised Patients DOI
Jonathon W. Senefeld, Michael J. Joyner

Clinical Infectious Diseases, Год журнала: 2023, Номер 77(7), С. 961 - 963

Опубликована: Июнь 18, 2023

Journal Article Corrected proof Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Replacement Therapy for Immunocompromised Patients Get access Jonathon W Senefeld, Senefeld Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USADepartment Physiology Biomedical Engineering, USA https://orcid.org/0000-0001-8116-3538 Search other works by this author on: Oxford Academic PubMed Google Scholar Michael J Joyner Correspondence: M. Joyner, 200 First Street SW, MN 55905, ([email protected]). https://orcid.org/0000-0002-7135-7643 Clinical Infectious Diseases, ciad367, https://doi.org/10.1093/cid/ciad367 Published: 20 June 2023 history Received: 23 May Editorial decision: 30 Accepted: 17 typeset: 09 August

Язык: Английский

Процитировано

2
Secondary organizing pneumonia associated with protracted COVID: A case series DOI Creative Commons

P-Y. Sansen,

Emmanuel Coche, Pierre Hainaut

и другие.

Infectious Diseases Now, Год журнала: 2024, Номер 54(3), С. 104888 - 104888

Опубликована: Март 15, 2024

Immunocompromised B-cell-depleted patients are at risk of developing protracted COVID-19, a clinical syndrome characterized by prolonged viral shedding and respiratory symptoms that can lead to hypoxemic pneumonia. Our aim is describe this unusual condition its treatment. This monocentric retrospective study reports six cases severe organizing pneumonia developed during the course COVID-19. All (OP) in setting COVID. Clinical improvement was obtained after several treatment lines including specific antiviral agents occurred simultaneously with control load. As it most frequent presentation COVID-19 our survey, we believe form warrants increased awareness. Furthermore, therapy seems condition.

Язык: Английский

Процитировано

0
Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era DOI Creative Commons
Dong Won Baek, Ga‐Young Song, Ho Sup Lee

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Апрель 23, 2024

Elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergoing reduced intensity R-CHOP therapy are at a heightened risk of acquiring infections, notably coronavirus disease 2019 (COVID-19) infection. This study aimed to evaluate the efficacy intravenous immunoglobulin (IVIG) as prophylaxis against COVID-19 in this vulnerable population. A total 125 elderly DLBCL were analyzed prospective, multicenter study. Patients hypogammaglobulinemia categorized into IVIG and non-IVIG groups, while those normal levels constituted observation group. The evaluated infection rates, response, safety outcomes. Among enrolled (median age: 77 years), 89 (71.2%) presented diagnosis, 56 administration remarkably rates compared recipients (8.9% vs. 24.6%; p =0.040). Notably, over 80 years old more susceptible COVID-19. on exhibited good tolerance manageable adverse events. who received IVIG, 40.5% developed additional deficiencies during chemotherapy. One or new occurred chemotherapy 72% did not receive 61.3% have diagnosis. showed promise reducing infections among receiving therapy. highlights IVIG's potential prophylactic measure, necessitating further investigation optimize dosing, schedules, interactions vaccination strategies.

Язык: Английский

Процитировано

0
A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir DOI Creative Commons
Luke B. Snell, Aimée McGreal-Bellone, Clemency Nye

и другие.

Open Forum Infectious Diseases, Год журнала: 2023, Номер 11(1)

Опубликована: Дек. 7, 2023

The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where SARS-CoV-2 was successfully treated prolonged courses (median, 10 days [range, 10-18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most (9/11) had hematological malignancy and (10/11) received CD20-depleting therapy. median duration 103 (interquartile range, 85-138 days). majority were hospitalized, 7 (7/11) severe/critical disease. All survived 9 demonstrated viral clearance, almost half (4/9) whom as monotherapy. This series suggests that has a role treating infection.

Язык: Английский

Процитировано

1